Evidence map›Paper›PMID 34491807›Full record

ArticleAntimicrobial agents and chemotherapy2021

Adjunctive Rifampicin Increases Antibiotic Efficacy in Group A Streptococcal Tissue Infection Models.

H Bergsten, L M Palma Medina, M Morgan, K Moll, D H Skutlaberg, S Skrede, T Wajima, M Svensson, A Norrby-Teglund

Open access · greenAbstract readCase Reports
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Virulence · 2026
    Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Antibiotics againstPharmaceutics · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 4 countries.

H BergstenCenter for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden.
L M Palma MedinaCenter for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden.
M MorganRoyal Devon and Exeter Hospital, Exeter, United Kingdom.
K MollCenter for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden.
D H SkutlabergDepartment of Microbiology, Haukeland University Hospital, Bergen, Norway.
S SkredeDepartment of Clinical Science, University of Bergen, Bergen, Norway.
T WajimaDepartment of Microbiology, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.ORCID 0000-0001-9506-707X
M SvenssonCenter for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden.
A Norrby-TeglundCenter for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden.ORCID 0000-0001-9372-1795
Karolinska University Hospital · SEHaukeland University Hospital · NORoyal Devon and Exeter Hospital · GBTokyo University of Pharmacy and Life Sciences · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biofilm has recently been highlighted as a complicating feature of necrotizing soft tissue infections (NSTI) caused by Streptococcus pyogenes (i.e., group A Streptococcus [GAS]) contributing to a persistence of bacteria in tissue despite prolonged antibiotic therapy. Here, we assessed the standard treatment of benzylpenicillin and clindamycin with or without rifampin in a tissue-like setting. Antibiotic efficacy was evaluated by CFU determination in a human organotypic skin model infected for 24 or 48 h with GAS strains isolated from NSTI patients. Antibiotic effect was also evaluated by microcalorimetric metabolic assessment in

Indexed as

Soft Tissue InfectionsStreptococcal InfectionsAnti-Bacterial AgentsHumansRifampinStreptococcus pyogenesAnti-Bacterial AgentsRifampinbiofilmnecrotizing soft tissue infectionsrifampicinStreptococcus pyogenes

Identifiers

PMID34491807
PMCPMC8522778
OpenAlexW3197410080

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.